Halozyme Therapeutics, Inc.
HALO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $6,064 | $4,876 | $7,786 | $5,655 |
| - Cash | $116 | $118 | $234 | $119 |
| + Debt | $1,506 | $1,499 | $1,506 | $877 |
| Enterprise Value | $7,454 | $6,257 | $9,058 | $6,413 |
| Revenue | $1,015 | $829 | $660 | $443 |
| % Growth | 22.4% | 25.6% | 48.9% | – |
| Gross Profit | $856 | $637 | $521 | $362 |
| % Margin | 84.3% | 76.8% | 78.9% | 81.6% |
| EBITDA | $657 | $452 | $316 | $259 |
| % Margin | 64.7% | 54.5% | 47.8% | 58.4% |
| Net Income | $444 | $282 | $202 | $403 |
| % Margin | 43.7% | 34% | 30.6% | 90.8% |
| EPS Diluted | 3.43 | 2.1 | 1.44 | 2.74 |
| % Growth | 63.3% | 45.8% | -47.4% | – |
| Operating Cash Flow | $479 | $389 | $240 | $299 |
| Capital Expenditures | -$11 | -$15 | -$5 | -$1 |
| Free Cash Flow | $468 | $373 | $235 | $298 |